NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V.
Your view on NAMS
Overview
What the company does, where it operates, and who runs it.
About NewAmsterdam Pharma Company N.V.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Harvey Davidson Facp.
- Headquarters
- NL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Harvey Davidson Facp.
- Headquarters
- NL
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C).
The company was founded in 2019 and is based in Naarden, the Netherlands.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for NewAmsterdam Pharma Company N.V., and the rating behind it. NAMS last traded at $20.50; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NewAmsterdam Pharma Company N.V.. Starting points for NewAmsterdam Pharma Company N.V.: EPS -$2.10, beta 0.10 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NewAmsterdam Pharma Company N.V.. Trailing twelve-month EPS for NewAmsterdam Pharma Company N.V. stands at -$2.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NewAmsterdam Pharma Company N.V.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NewAmsterdam Pharma Company N.V. valued side by side against its closest peers. NewAmsterdam Pharma Company N.V. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold NewAmsterdam Pharma Company N.V., and how their positions are changing. At a $2.40B market value, institutional positions materially move NewAmsterdam Pharma Company N.V.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by NewAmsterdam Pharma Company N.V. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. is a $2.40B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming NewAmsterdam Pharma Company N.V.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NewAmsterdam Pharma Company N.V.. Coverage tracks NewAmsterdam Pharma Company N.V. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.